3 US Penny Stocks With Market Caps Over $30M To Watch

In This Article:

After two days of record highs, the U.S. stock market saw a decline with major indices like the Dow Jones and Nasdaq posting losses. In such fluctuating conditions, investors often look for opportunities in various segments of the market, including penny stocks. Although considered an outdated term, penny stocks still represent smaller or newer companies that can offer both affordability and growth potential when backed by strong financials.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$132.89M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.78

$85.54M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.44

$47.85M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2695

$9.57M

★★★★★★

PHX Minerals (NYSE:PHX)

$4.20

$156.67M

★★★★★☆

Smith Micro Software (NasdaqCM:SMSI)

$1.43

$24.83M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8696

$79.96M

★★★★★☆

BAB (OTCPK:BABB)

$0.83

$6.31M

★★★★★☆

Lifetime Brands (NasdaqGS:LCUT)

$4.95

$110.78M

★★★★★☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Aadi Bioscience

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers involving mTOR pathway gene alterations, with a market cap of $70.74 million.

Operations: The company generates revenue of $25.07 million from its segment focused on the development and commercialization of proprietary therapeutics.

Market Cap: $70.74M

Aadi Bioscience, Inc., with a market cap of US$70.74 million, is navigating significant strategic shifts amid its unprofitable status and volatile share price. The recent appointment of Dr. David Dornan as Chief Scientific Officer underscores the company's focus on advancing its portfolio of antibody-drug conjugates (ADCs). Aadi's strategic plan includes selling FYARRO® for US$100 million and acquiring ADC assets from WuXi Biologics, supported by a US$100 million private placement financing. Despite financial challenges, Aadi remains debt-free with sufficient short-term assets to cover liabilities and an experienced board guiding these transformative efforts.

NasdaqCM:AADI Debt to Equity History and Analysis as at Feb 2025
NasdaqCM:AADI Debt to Equity History and Analysis as at Feb 2025

PodcastOne

Simply Wall St Financial Health Rating: ★★★★☆☆